Litcius/Paper detail

Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency

Sara Barmettler, Daniel DiGiacomo, Nancy Yang, Tiffany Lam, Vivek Naranbhai, Anand S. Dighe, Kristin E. Burke, Kimberly G. Blumenthal, Morris Ling, Paul E. Hesterberg, Rebecca R. Saff, James A. MacLean, Onosereme Ofoman, Cristhian Berrios, Kerri St. Denis, Evan C. Lam, David J. Gregory, A. John Iafrate, Mark C. Poznansky, Hang Lee, Alejandro B. Balazs, Shiv Pillai, Jocelyn R. Farmer

2022The Journal of Allergy and Clinical Immunology In Practice24 citationsDOIOpen Access PDF

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakRespiratory systemCoronavirusAntibodyBetacoronavirusVirologyImmunologyInternal medicineOutbreakDiseaseInfectious disease (medical specialty)Immunodeficiency and Autoimmune DisordersSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies
Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency | Litcius